Quick Answer
Life sciences QMS software manages regulated quality processes and records across pharma, biotech, biologics, diagnostics, and medical devices. The right system depends on the product type: drug and biologic manufacturers need GMP and ICH Q10 support, while device manufacturers need QMSR and ISO 13485 alignment. Across all life sciences teams, Part 11, document control, CAPA, change control, deviations, complaints, audits, and training are common requirements.
Key Takeaways
- Life sciences QMS software must support regulated records, not only workflow routing.
- Pharma and biotech teams usually anchor requirements in GMP, ICH Q10, and Part 11.
- Medical device teams anchor requirements in FDA QMSR, ISO 13485, Part 820, and Part 11 where applicable.
- The best QMS software connects quality events to regulatory impact and submission readiness.
- A single eQMS can support multiple product types, but configuration must match the applicable regulatory framework.
- Life sciences QMS software is different from generic quality software because the records may support patient safety, product release, inspections, regulatory submissions, and postmarket obligations. A task that looks operational in a normal business can become regulated evidence in a pharma, biotech, or medical device company.
- This guide explains how to think about QMS software across product types and where regulatory-readiness workflows fit.
- The key distinction is evidence. A generic QMS may route approvals and track tasks. A life sciences QMS must preserve controlled records, signatures, audit trails, version history, retention, and retrieval in a way that can survive inspection, submission review, partner due diligence, and internal quality review.
- The system also has to fit the product type. A device startup preparing eSTAR evidence has different needs from a biologics company preparing BLA Module 3 records or a commercial pharma manufacturer managing GMP deviations and post-approval changes.
What Life Sciences QMS Software Should Do
| Core Workflow | Why It Matters |
|---|---|
| Document control | Keeps procedures, specifications, and protocols approved and current |
| Training | Links personnel qualification to effective procedures |
| Deviations and nonconformance | Captures departures from approved process or specification |
| CAPA | Drives corrective and preventive action from quality signals |
| Change control | Controls changes and regulatory impact assessment |
| Supplier quality | Manages suppliers, audits, and quality agreements |
| Complaints | Captures postmarket quality and safety signals |
| Audits | Supports internal, supplier, and regulatory inspection readiness |
| Management review | Trends quality system performance and escalations |
These workflows should share data. A complaint may open an investigation, trigger CAPA, require a field action assessment, and create a regulatory reporting decision.
Shared Data Matters
A life sciences QMS becomes more valuable when records share product, site, supplier, process, market, and application context. Without that context, teams can close records but still struggle to answer basic questions:
- Which CAPA affect this product?
- Which open deviations affect this batch or site?
- Which supplier changes affect a registered market?
- Which training records support this procedure version?
- Which validation report supports this submission statement?
- Which change controls require regulatory assessment?
Those questions are where quality operations and regulatory operations meet.
What Makes a Life Sciences QMS Different From Generic Workflow Software
A generic workflow tool can assign tasks, collect approvals, and store attachments. A life sciences QMS must preserve regulated meaning.
That means the system should support:
- Controlled document versions and effective dates
- Role-based training tied to current procedures
- Audit trails for regulated record changes
- Electronic signatures where signatures are electronic regulated signatures
- Record retention and retrieval by product, site, lot, supplier, process, or date
- Investigation and impact-assessment logic
- Links between quality events, change records, CAPA, suppliers, and regulatory decisions
- Validation or assurance evidence for intended use
These controls matter because the record may later support a batch disposition decision, FDA inspection, partner diligence request, health authority response, eCTD section, or eSTAR attachment.
Pharma, Biotech, and Device Requirements Differ
| Product Type | Main QMS Context |
|---|---|
| Pharma | 21 CFR Part 211, ICH Q10, GMP records, Part 11 where applicable |
| Biologics | GMP expectations plus biologics-specific product and facility records |
| Medical devices | FDA QMSR, ISO 13485, Part 820, postmarket device reporting |
| Combination products | Quality expectations may span drug, biologic, and device constituent parts |
The same software can support these needs only if the configuration, procedures, validation, and record taxonomy are designed around the applicable product type.
Product-Type Differences in Practice
Pharma
Pharma teams usually need strong deviation, CAPA, change control, supplier quality, validation, batch-related records, laboratory records, and inspection retrieval. Change control should include regulatory impact assessment because CMC content, specifications, manufacturing process, sites, and container closure information may be affected.
Biotech and Biologics
Biotech teams often need flexible workflows for outsourced development and manufacturing. CDMO oversight, quality agreements, CMC document control, process validation, comparability, stability, and BLA readiness become central as the program matures.
Medical Devices
Device teams need design controls, risk management, supplier quality, complaint handling, CAPA, software evidence, labeling, and eSTAR-ready evidence. After FDA's QMSR effective date, device teams also need to understand the QMSR/ISO 13485 operating model.
Combination Products
Combination products may need drug, biologic, and device quality considerations. The QMS should make product-specific responsibilities clear and avoid assuming a single workflow fits all constituent parts.
Regulatory Readiness Is the Differentiator
Many QMS tools can route approvals. Fewer help teams understand whether quality records are ready for inspection or submission use.
A life sciences QMS should make it easy to answer:
- What is the current approved document?
- Who approved it and when?
- What records were created under that version?
- Which deviations or CAPAs affect this product?
- Which changes require regulatory assessment?
- Which quality records support an eCTD or eSTAR filing?
That last question is where QMS and regulatory operations meet.
Part 11, Validation, and Intended Use
Life sciences QMS software often manages regulated electronic records or electronic signatures. Part 11 may apply depending on the record, signature, and intended use. The company should evaluate audit trails, access controls, electronic signatures, record retention, accurate copies, and validation evidence.
Validation should be risk-based and tied to intended use. The system used only for draft planning does not carry the same risk as the system used for official CAPA, change control, deviation closure, training records, or product release evidence.
Buyers should ask vendors for validation documentation, release notes, audit trail design, electronic signature controls, data export, configuration documentation, and customer validation responsibilities.
Implementation Order
Most life sciences teams should implement in phases:
- Document control
- Training
- Deviations or nonconformances
- CAPA
- Change control and regulatory impact assessment
- Supplier quality
- Audit management
- Complaints and postmarket workflows, where applicable
- Management review and quality metrics
The order may change by product type. A device startup may prioritize design controls earlier. A virtual biotech may prioritize CDMO oversight. A commercial manufacturer may need deviation and CAPA earlier than a preclinical team.
How Assyro Connects QMS to Submissions
Submission defects often originate upstream in quality records. Regulatory Gap Analysis, eCTD Validation, eSTAR Validation, and QMS document control software help teams find those gaps before they become filing or inspection problems.
For more context, see QMS vs RIM, QMS and RIM in one platform, quality-to-regulatory operating system, and best QMS and RIM software for life sciences.
The goal is not to claim that QMS software writes the submission. The goal is to make sure controlled evidence is complete, consistent, and ready when the submission team needs it.
The practical bridge is source evidence in quality, regulatory context in RIM, and submission-ready outputs when the team needs to answer an FDA or health authority question. That is especially important for teams that need better control of records that affect filings.
Vendor Demo Scenarios
Ask vendors to demonstrate scenarios that cross product types and functions:
- A pharma process change affects a filed Module 3 process description.
- A biotech CDMO deviation affects batch disposition and IND amendment support.
- A device complaint trend opens CAPA and updates risk management evidence.
- A supplier change affects a component, material, or testing method used across products.
- A document revision triggers training before the procedure becomes effective.
- An inspection request asks for the source records behind a submission statement.
The demo should show source records, approvals, audit trail, impact assessment, linked tasks, and record export. If the vendor can only show isolated forms, the system may not support the real handoff between quality and regulatory work.
Vendor Evaluation Questions
- Which product types does the vendor support deeply?
- Can workflows be configured differently for pharma, biotech, device, or combination products?
- Can quality records link to products, sites, markets, and applications?
- Can change control include regulatory impact assessment?
- Can records be retrieved with version, approval, signature, and audit-trail context?
- What validation package is available?
- How are SaaS releases managed?
- Can the system connect quality records to regulatory application and submission context?
It is software used by regulated life sciences companies to manage quality processes and records such as documents, training, deviations, CAPA, change control, suppliers, complaints, audits, and inspections.
References
This guide reflects FDA and ICH information current as of May 2026. Confirm product-specific regulatory obligations before configuring a life sciences QMS.
About the author
Assyro Team
Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.
See Assyro in action
Catch eCTD and eSTAR errors before your FDA review cycle.
Book a 20-minute demo this week. We'll validate a sample of your submission live and show you exactly where Assyro catches what your current QC misses.